You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
突發!又有A股董事長被立案調查,公司股價年內跌近18%

A股又見上市公司董事長被立案調查。

7月6日晚,新里程(002219.SZ)公告稱,公司董事長林楊林被留置並立案調查

截止上週五收盤,公司收跌1.3%報2.17元,總市值73.51億元。

今年迄今,該股累計下跌近18%。

董事長被立案調查

新里程公告,公司董事長林楊林被太原市小店區監察委員會實施留置並立案調查,無法履職。

根據《公司章程》,董事許銘桂在林楊林無法履職期間代爲履行董事長職責。

公告稱,公司已確認董事長林楊林所涉事項與公司無關。截至本公告日,公司未被要求協助調查。

目前,其他董事、監事、高級管理人員均正常履職,公司及子公司生產經營情況一切正常,本事項預計不會對公司生產經營造成實質性重大不利影響。

公開資料顯示,林楊林於1981年出生,曾任北大醫療產業基金管理有限公司CEO;現任新里程健康集團有限公司CEO,北京新里程健康產業集團有限公司董事長,新里程健康科技集團股份有限公司董事長。

公司持股方面,截至2024年末,林楊林持有新里程2600萬股股份。

值得一提的是,今年6月下旬,林楊林和公司財務總監劉軍曾遭甘肅證監局約談。

據悉,因財務會計覈算不規範導致2023年度至2024年第三季度財務數據披露不準確,甘肅證監局此前對新里程採取責令改正措施

另因未能勤勉盡責,董事長林楊林和財務總監劉軍甘肅證監局監管談話。

業績連續承壓

信息顯示,新里程成立於2001年,是一家以從事衛生爲主的企業。

企業註冊資本326416.3753萬人民幣,法定代表人爲林楊林。

公司前身爲甘肅獨一味生物製藥有限責任公司。2008年3月,新里程登陸A股。

現主營業務已涵蓋醫療服務、藥品製造等業務領域。

2022年,新里程健康集團通過破產重整控股了恆康醫療,並於2022年9月將證券簡稱由“恆康醫療”變更爲“新里程”。

從近年業績來看,公司面臨短期經營壓力與長期轉型機遇並存的局面。

回顧2024全年,新里程錄得營收38億元,同比下滑2.95%;淨利潤1.15億元,同比增長296.13%。

今年一季度,新里程營收7.96億元,同比下滑16.49%;歸屬於上市公司股東的淨利潤2565.19萬元,同比減少9.35%。

經營活動現金流淨額由正轉負至-3799萬元,同比銳減295.69%。

這里值得關注的是,自2024年第三季度起,新里程營收已連續3個季度同比下滑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account